NDA 219776 · Biocryst
Orladeyo
Berotralstat Dihydrochloride · Oral
Priority reviewOrphanLast checked: Nov 20, 2026Latest source record: Dec 11, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2025
Dec 11, 2025
Approved uses
1
Original approval plus efficacy supplements
Registered trials
0
0 Phase 3, 0 recruiting
FAERS reports
911
434 serious, 28 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 23, 2026.
ORLADEYO ® is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 2 years of age and older. ORLADEYO is a plasma kallikrein inhibitor indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 2 years and older. ( 1 ) Limitations of Use : ORLADEYO should not be used for treatment of acute HAE attacks. ( 1 ) Limitations of Use : The safety and effectiveness of ORLADEYO for the treatment of acute HAE attacks have not been established. ORLADEYO should not be used for treatment of acute HAE attacks. Additional doses or doses of ORLADEYO higher than the prescribed once-daily dose are not recommended due to the potential for QTc interval prolongation [see Warnings and Precautions (5.1) ] .
Mechanism: Berotralstat is a plasma kallikrein inhibitor that binds to plasma kallikrein and inhibits its proteolytic activity. Plasma kallikrein is a protease that cleaves high-molecular-weight kininogen (HMWK) to generate cleaved HMWK (cHMWK) and bradykinin, a potent vasodilator that increases vascular permeability resulting in swelling and pain associated with HAE. In patients with HAE due to C1-inhibitor (C1-INH) deficiency or dysfunction, normal regulation of plasma kallikrein activity is not present, which leads to uncontrolled increases in plasma kallikrein activity and results in angioedema...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
5 products under this application
- ORLADEYO · BEROTRALSTAT DIHYDROCHLORIDE EQ 132MG BASE/PACKET · PELLETS, ORAL · Prescription
- ORLADEYO · BEROTRALSTAT DIHYDROCHLORIDE EQ 96MG BASE/PACKET · PELLETS, ORAL · Prescription
- ORLADEYO · BEROTRALSTAT DIHYDROCHLORIDE EQ 150MG BASE/PACKET · PELLETS, ORAL · Prescription
- ORLADEYO · BEROTRALSTAT DIHYDROCHLORIDE EQ 108MG BASE/PACKET · PELLETS, ORAL · Prescription
- ORLADEYO · BEROTRALSTAT DIHYDROCHLORIDE EQ 72MG BASE/PACKET · PELLETS, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Berotralstat Dihydrochloride" as an intervention, any sponsor and status, largest first.
No registered drug trials name this ingredient.
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- hereditary angioedema258
- nausea63
- diarrhoea62
- drug ineffective61
- headache56
- abdominal pain52
- gastrointestinal disorder50
- condition aggravated47
- fatigue44
- vomiting40
- malaise37
- abdominal pain upper36
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2019 | 1 |
| 2020 | 5 |
| 2021 | 70 |
| 2022 | 86 |
| 2023 | 105 |
| 2024 | 201 |
| 2025 | 308 |
| 2026 | 135 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Orladeyo (Berotralstat Hydrochloride)
2024 spending
$77.9M
Beneficiaries
221
1,835 claims
Per beneficiary
$352,465
$1,516.05 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $26,481,757 |
| 2022 | $47,943,573 |
| 2023 | $52,329,473 |
| 2024 | $77,894,703 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
No PubMed clinical studies matched.
Sponsor: Biocryst
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.